Harbour BioMed Appoints Michael D. Patten as Chief Strategy Officer to Lead Global Growth
China-based Harbour BioMed (HKG: 2142) announced the appointment of Michael D. Patten as Chief Strategy...
Company
Genmab’s HexaBody-CD38 Clinical Development Halted After J&J Opt-Out
Denmark-based Genmab A/S (NASDAQ: GMAB) announced that US giant Johnson & Johnson (J&J, NYSE: JNJ)...
Sichuan Kelun-Biotech’s Sacituzumab Tirumotecan Wins New NMPA Approval for NSCLC
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced receiving another indication approval from the...
Illumina Responds to Chinese MOFCOM Notice Amid Sequencing Instrument Export Ban
US major Illumina (NASDAQ: ILMN), which was included in a list of unreliable entities issued...
Huadong Medicine Seeks Regular Approval for Elahere in Ovarian Cancer Treatment
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its application for converting conditional to...
Hansoh Pharmaceutical’s Ameile Wins New NMPA Approval for Advanced NSCLC Treatment
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced receiving another indication approval from the...
IMEIK Technology Development Co.,Ltd Acquires Majority Stake in REGEN Biotech via Joint Venture
China-based IMEIK Technology Development Co.,Ltd (SHE: 300896) announced the establishment of Imeik International Limited, a...
Lundbeck’s Amlenetug Receives Orphan Drug Designation in Japan for Multiple System Atrophy
Denmark-based pharmaceutical company Lundbeck A/S (OTCMKTS: HLUBF) announced receiving Orphan Drug Designation (ODD) from Japan’s...
Shenzhen GeneMind Biosciences Partners with Precisiongenes for Molecular Diagnostic Innovation
China-based gene sequencer specialist Shenzhen GeneMind Biosciences Co., Ltd. has formed a partnership with compatriot...
Juvensis Therapeutics Secures RMB100 Million for Heart Gene Therapy Development
Shanghai-based Juvensis Therapeutics, a specialist in anti-aging therapies, reportedly raised upwards of RMB100 million (USD13.8...
Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for HRS-4029 in Acute Ischemic Stroke
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced receiving clinical trial approval from the...
InnoCare Pharma Presents Positive Phase II Results of ICP-488 in Psoriasis at AAD Meeting
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) announced the oral presentation of results from the...
Nona Biosciences Launches Hu-mAtrIx: AI-Driven Engine for Accelerated Antibody Drug Discovery
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), announced the introduction of...
Sichuan Biokin Pharmaceutical Plans RMB3.9 Billion Private Placement for Novel Drug R&D
China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced plans to raise up to RMB3.9...
LiteDD’s LIT0922 Approved for Phase I Trial in Marker-Expressing Advanced Solid Tumors
The Center for Drug Evaluation (CDE) of China has approved LiteDD’s Category 1 product LIT0922...
Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for SHR-4602 Clinical Study in Advanced Solid Tumors
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced receiving approval from the National Medical...
Jiangsu Cowin Biotech Obtains NMPA License for Gene Methylation Detection Kit
China-based Jiangsu Cowin Biotech Co., Ltd. (SHA: 688426) announced receiving a Category III medical device...
InventisBio Announces Positive Phase II Results for D-2570 in Psoriasis Treatment
China-based InventisBio (Shanghai) Co., Ltd (SHA: 688382) announced positive results from the Phase II study...
Bristol-Myers Squibb’s Opdivo/Yervoy Combo Approved by EU for Hepatocellular Carcinoma
US giant Bristol-Myers Squibb (BMS, NYSE: BMY) announced receiving marketing approval from the European Commission...
Roche Launches Genentech Innovation Center in Boston to Accelerate Drug Development
Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced the launch of the Roche Genentech Innovation...